Logo of Resonance Health (ASX:RHT)Latest Resonance Health (ASX:RHT) News

Page 1
Page 1 of 3

Resonance Health turns profitable as it funds its next growth phase

Resonance Health delivered a $1.5 million profit and positive operating cash flow in every quarter of FY26, while raising $6 million to accelerate three growth programmes. The challenge is replacing a MASH trial that generated 48% of last year’s revenue.
Ada Torres
19 Nov 2026

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Resonance Health finds MRI fibrosis signal in 50-subject study

Resonance Health has reported encouraging preliminary results from an investigational MRI software device that identifies liver fibrosis without additional scanner hardware. The early data are promising, but the model remains unverified and regulatory clearance is still ahead.
Ada Torres
28 Oct 2026

Resonance Health raises $6 million as preliminary fibrosis data opens next growth phase

Resonance Health has secured an oversubscribed $6.0 million placement to fund MRI endpoint expansion, new TrialsWest sites and development of its non-invasive liver fibrosis device. The raise lifts pro forma net cash to $7.9 million, but the most consequential project remains an investigational technology backed by a small preliminary dataset.
Victor Sage
27 Oct 2026

Resonance Health Opens Global Route for MRI Trial Endpoints Through IAG Alliance

Resonance Health has signed a 24-month alliance with London-based Image Analysis Group, making its quantitative MRI endpoints orderable across IAG’s global clinical-trial network. The opportunity is potentially significant, but remains uncontracted: two pilot studies come first, with no minimum revenue or volume commitments.
Victor Sage
17 Sept 2026

Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.
Logan Eniac
29 Aug 2026

Resonance Health Delivers $1.5M Profit on 42% Revenue Surge in FY26

Resonance Health (ASX: RHT) reported a profitable turnaround in FY26, driven by growth across its imaging software, clinical trial services, and site network businesses.
Ada Torres
28 Aug 2026

Healthcare Wrap - Week 30 (20 July -> 24 July) 2026

Lumos led healthcare stocks higher after widening its US urgent care rollout, while Tissue Repair tumbled on its plan to leave the ASX. Strong trial updates, FDA steps and fresh funding kept the sector busy, even as several stocks fell despite good news.
Logan Eniac
25 July 2026

Resonance Health Posts Full-Year Positive Cash Flow and Clinical Trial Milestone

Resonance Health (ASX:RHT) closed FY26 with a net operating cash inflow of $2.9 million and completed recruitment for a $13.8 million clinical trial, underpinning a robust contract pipeline and growing net cash position.
Ada Torres
24 July 2026

Market Wrap - Week 24 (8 June -> 12 June) 2026

A brutal sell-off in a few small caps sat alongside takeover bids, fresh capital raisings and strong gains in medtech. The week split the market in two: buyers chased clear funding and approval news, while weaker stories sank fast after reopening.
Logan Eniac
13 June 2026

Healthcare Wrap - Week 24 (8 June -> 12 June) 2026

Healthcare shares were driven by regulation, capital and commercial deals this week. The biggest moves came from companies that either moved closer to US sales or raised cash to get there.
Logan Eniac
13 June 2026

Resonance Health Advances Non-Invasive Liver Fibrosis MRI Device Amid FY26 Growth

Resonance Health is progressing its MRI Liver Fibrosis device through late-stage clinical validation, targeting FDA biomarker qualification, while maintaining a profitable SaaMD platform and forecasting $16 million revenue for FY26.
Ada Torres
9 June 2026